Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.

Objectives: To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee.

Design: A 6-week, randomized, parallel-group, double-blind, placebo-controlled study.

Setting: One hundred thirteen outpatient sites in the United States.

Regulation of concanavalin A-activated suppressor cell activity by interferon.

In addition to its antiviral activity, interferon (IF) has been shown to have a wide range of immunoregulatory effects in vivo and in vitro. IF has been observed to be produced by concanavalin A (Con A)-activated suppressor cells and has also been postulated to be of importance in modulating their suppressor activity. To explore this possibility further, we examined the capacity of interferon-treated Con A-activated suppressor cells to alter the normal mitogenic response to Con A.

Ankylosing spondylitis in men and women: a clinical and radiographic comparison.

Thirty-one men and 32 women with ankylosing spondylitis (AS) were evaluated to determine if there are notable differences between the sexes in the nature and course of this disease. The average age at onset was 22 years in women and 23 years in men. Eighteen men, but only eight women, had persistent spinal disease.